![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI/S) | LSE:TYR | London | Ordinary Share | COM SHS USD0.001 (DI / REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.95 | 2.70 | 3.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTYR TIDMTYRU
RNS Number : 6343L
TyraTech, Inc.
14 August 2013
14 August 2013
TyraTech, Inc.
("TyraTech" or the "Company")
TyraTech announces global agreement for distribution of biocide products
TyraTech (AIM: TYR and TYRU), a life sciences company focusing on natural insect and parasite control products, announces that it has entered into a global distribution partnership with a leading global Animal Health company to distribute a range of TyraTech's biocide products on a worldwide basis. These biocide products will be used in production animal facilities and premises to control flies, cockroaches and other insects.
The agreement with Novartis Animal Health, Inc. potentially enables a rapid, efficient route to market for some of TyraTech's animal health products. TyraTech's breakthrough technology provides a safe, effective, and environmentally-conscious solution to control insects in animal premises that cause both a health risk and significant economic losses to farmers.
This announcement is in line with TyraTech's previous announcement, dated 27 June 2013, where the Company disclosed discussions with major global animal health partners to commercialise some of its existing and pipeline products. TyraTech continues to pursue other opportunities with consumer products companies to market TyraTech's existing and future personal care products.
Commenting, Bruno Jactel, Chief Executive Officer of TyraTech said: "This agreement demonstrates the effectiveness and quality of our technology and product set. TyraTech has successfully developed and productised solutions to a number of significant worldwide problems for both animal and human health where no comparable solutions, in terms of efficacy and safety, currently exist. These problems represent multi-billion dollar markets in which TyraTech has the potential to be a significant player. We look forward to working with Novartis Animal Health and to seeing the biocide products successfully introduced to the market."
For further information please contact:
TyraTech Inc.
Alan Reade, Non-Executive Chairman
Tel: +44 7841978709
Bruno Jactel, Chief Executive Officer
Tel: +1 919 415 4340
N+1 Singer, Nominated Adviser and Joint Broker
Jonny Franklin-Adams / Alex Wright
Tel: +44 20 7496 3000
First Columbus LLP, Joint Broker
Chris Crawford
Tel: +44 20 3002 2070
Walbrook, Financial PR and IR
Bob Huxford /Guy McDougall (Public Relations)
Tel + 44 7933 8792
Paul Cornelius (Investor Relations)
Tel +44 20 7933 8794
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRLFFSLTFIVLIV
1 Year Tyratech Chart |
1 Month Tyratech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions